An observational study in Heart Failure, sponsored by Qianfoshan Hospital. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-12-06.
Sponsored by Qianfoshan Hospital · Observational
The goal of this observational study is to assess the effect of the different combination of drugs in the treatment of heart failure.
The main questions it aims to answer are:
Participants will be asked to do nothing. All the records of the patients will be download from the Big Data Cloud Platform of Health Care in the First Affiliated Hospital of Shandong First Medical University.
There is not a comparison group.
The purpose of this study is to evaluate the efficacy and cost-effective of different drugs co-administration in the treatment of heart failure. For different reasons, patients with heart failure took different drug prescriptions. Now there are five kinds of drugs for the treatment of heart failure, such as angiotensin converting enzyme inhibitor or angiotensin receptor blocker (ACEI/ARB), beta-blokers, spironolactone, sodium-glucose cotransporter (sglt) 2 inhibitors and vericiguat. Our purpose is to assessment the efficacy and cost-effective of different drugs co-administration in the treatment of heart failure.
5,701 studies on the registry are indexed under Heart Failure; 1,220 are open to participants now.
This study's planned enrollment of 702 is above the median of 200 across 1,679 observational studies indexed under Heart Failure.
Browse Heart Failure studies →Qianfoshan Hospital is the lead sponsor of 140 studies on the registry; 73 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The hospitalized patients who were treated in the First Affiliated Hospital of Shandong First Medical School from January 2013.to October 2023
Exclusion Criteria:
single drug group, patients with heart failure only took one sort of drugs two drugs group, patients with heart failure took two sorts of drugs three drugs group, patients with heart failure took three sorts of drugs four drugs group, patients with heart failure took four sorts of drugs
The B-type natriuretic peptide (BNP)
B-type natriuretic peptide (BNP) is a marker of heart failure. Its levels can be measured with a rapid and commercially available bed-side assay. Rising levels correlate with the degree of left ventricular dysfunction and severity of symptoms.
Time frame: Admission to hospital and 12 months thereafter
Left ventricular ejection fraction (LVEF) of patients
Echocardiography is the gold standard for establishing the presence of left ventricular dysfunction. Left ventricular ejection fraction (LVEF) is the central measure of left ventricular systolic function. LVEF is the fraction of chamber volume ejected in systole (stroke volume) in relation to the volume of the blood in the ventricle at the end of diastole (end-diastolic volume).
Time frame: Admission to hospital and 12 months thereafter
Hospital mortality
We recorded the death from heart failure, no matter the mode of death.
Time frame: Index hospital stay
Days of hospitalization and expenses of patients
The hospitalization days and expenses of patients admitted with different drugs treatment were examined.
Time frame: Index hospital stay
degree of lower limb edema (mild, moderate, severe)
Lower-extremity edema is one of the important factors in diagnosing, monitoring, and managing HF status. A senior cardiologist checked carefully for the presence of bilateral lower-extremity edema and graded its severity on a scale of 1 of 4 based on the extent of the edema in the leg, as follows: (1) none, (2) up to the height of the ankle level (mild edema), (3) up to the height of the knee (moderate edema), and (4) higher than knee level (severe edema).
Time frame: Admission to hospital and 12 months thereafter
6-minute walking test
The 6-minute walking test (6MWT) is a widely available and well-tolerated test for the assessment of the functional capacity of patients with HF.
Time frame: Admission to hospital and 12 months thereafter
No study locations are listed for this record.
Plan to share: Yes — patient characteristics and clinical outcomes
Supporting information: Study protocol, Sap
This study is not yet recruiting, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Qianfoshan Hospital